Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention

Background Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International urology and nephrology 2015-03, Vol.47 (3), p.521-525
Hauptverfasser: Firouzi, Ata, Maadani, Mohsen, Kiani, Reza, Shakerian, Farshad, Sanati, Hamid Reza, Zahedmehr, Ali, Nabavi, Seyedabbas, Heidarali, Mona
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 525
container_issue 3
container_start_page 521
container_title International urology and nephrology
container_volume 47
creator Firouzi, Ata
Maadani, Mohsen
Kiani, Reza
Shakerian, Farshad
Sanati, Hamid Reza
Zahedmehr, Ali
Nabavi, Seyedabbas
Heidarali, Mona
description Background Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CI-AKI and various agents tested for its prevention. There is currently a general agreement that adequate pre-procedural hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested IV magnesium sulfate (Mg) for CI-AKI prevention. Method and design This study is a prospective, randomized, open-labeled, single-center clinical trial. We randomly assigned 122 consecutive patients to two groups. The first group was the control group with routine treatment ( n  = 64), and second group was the study group with routine treatment plus IV magnesium sulfate 1 g just before the procedure ( n  = 62). Serum creatinine was measured before the procedure and 2 days after the procedure. The primary end point was the occurrence of CI-AKI within 48 h. CI-AKI was defined as 0.5 mg/dl or more increase in serum creatinine or 25 % or more increase above baseline serum creatinine. There was no difference in definition if both of these parameters were present. Results The control and study groups were comparable in the overall predicted risk of CI-AKI. Also, the type and volume of the contrast were not significantly different between the two groups. Following angioplasty, CI-AKI occurred in 17 (26.6 %) patients in the control group and nine (14.5 %) patients in the study group; there was a significant reduction in CI-AKI in the study group ( P  = 0.01). Additionally, there was no mortality or a need for hemodialysis in either group. Conclusion In primary PCI patients, the prophylactic use of intravenous Mg can be recommended to be added to traditional hydration for CI-AKI prevention.
doi_str_mv 10.1007/s11255-014-0890-z
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1659770661</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3605313261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-faecaff5da804ea36e88fc40498178e1feec2edc9a80686b4b7293fd37602f693</originalsourceid><addsrcrecordid>eNp1kUFrFTEUhYMo9rX6A9xIwI2b6E1mJsm4k6K1UHCj65CXuemb8iYZk4zS7v3fZpiniOAqkPudc8_lEPKCwxsOoN5mzkXXMeAtA90De3hEdrxTDROdbh-THTTAGZeiOSPnOd8BQK8BnpIz0bWq473ckZ_XoST7HUNcMp3sbcA8LhPNy9Hbgu9owB90wnKIAx0DnRNWtIwx0Oipi6s2FzaGYXE4VHg-pDjbcrjf6HGy6Z7OmNxSbMB1h4sphvV3DAXTye0ZeeLtMePz03tBvn788OXyE7v5fHV9-f6GubYVhXmLznrfDVZDi7aRqLV3LbS95koj94hO4OD6Opda7tu9En3jh0ZJEF72zQV5vfnOKX5bMBczjdnh8biFM1x2vVIgJa_oq3_Qu7ikUNOtlG5qAqEqxTfKpZhzQm9ORxsOZu3IbB2Z2pFZOzIPVfPy5LzsJxz-KH6XUgGxAbmOwi2mv1b_1_UXgo6hOw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1658380427</pqid></control><display><type>article</type><title>Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Firouzi, Ata ; Maadani, Mohsen ; Kiani, Reza ; Shakerian, Farshad ; Sanati, Hamid Reza ; Zahedmehr, Ali ; Nabavi, Seyedabbas ; Heidarali, Mona</creator><creatorcontrib>Firouzi, Ata ; Maadani, Mohsen ; Kiani, Reza ; Shakerian, Farshad ; Sanati, Hamid Reza ; Zahedmehr, Ali ; Nabavi, Seyedabbas ; Heidarali, Mona</creatorcontrib><description>Background Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CI-AKI and various agents tested for its prevention. There is currently a general agreement that adequate pre-procedural hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested IV magnesium sulfate (Mg) for CI-AKI prevention. Method and design This study is a prospective, randomized, open-labeled, single-center clinical trial. We randomly assigned 122 consecutive patients to two groups. The first group was the control group with routine treatment ( n  = 64), and second group was the study group with routine treatment plus IV magnesium sulfate 1 g just before the procedure ( n  = 62). Serum creatinine was measured before the procedure and 2 days after the procedure. The primary end point was the occurrence of CI-AKI within 48 h. CI-AKI was defined as 0.5 mg/dl or more increase in serum creatinine or 25 % or more increase above baseline serum creatinine. There was no difference in definition if both of these parameters were present. Results The control and study groups were comparable in the overall predicted risk of CI-AKI. Also, the type and volume of the contrast were not significantly different between the two groups. Following angioplasty, CI-AKI occurred in 17 (26.6 %) patients in the control group and nine (14.5 %) patients in the study group; there was a significant reduction in CI-AKI in the study group ( P  = 0.01). Additionally, there was no mortality or a need for hemodialysis in either group. Conclusion In primary PCI patients, the prophylactic use of intravenous Mg can be recommended to be added to traditional hydration for CI-AKI prevention.</description><identifier>ISSN: 0301-1623</identifier><identifier>EISSN: 1573-2584</identifier><identifier>DOI: 10.1007/s11255-014-0890-z</identifier><identifier>PMID: 25475196</identifier><identifier>CODEN: IURNAE</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Acute Kidney Injury - blood ; Acute Kidney Injury - chemically induced ; Acute Kidney Injury - prevention &amp; control ; Administration, Intravenous ; Aged ; Calcium Channel Blockers - administration &amp; dosage ; Contrast Media - adverse effects ; Creatinine - blood ; Female ; Humans ; Magnesium Sulfate - administration &amp; dosage ; Male ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Nephrology ; Nephrology - Original Paper ; Percutaneous Coronary Intervention - adverse effects ; Prospective Studies ; Urology</subject><ispartof>International urology and nephrology, 2015-03, Vol.47 (3), p.521-525</ispartof><rights>Springer Science+Business Media Dordrecht 2014</rights><rights>Springer Science+Business Media Dordrecht 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-faecaff5da804ea36e88fc40498178e1feec2edc9a80686b4b7293fd37602f693</citedby><cites>FETCH-LOGICAL-c442t-faecaff5da804ea36e88fc40498178e1feec2edc9a80686b4b7293fd37602f693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11255-014-0890-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11255-014-0890-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27906,27907,41470,42539,51301</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25475196$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Firouzi, Ata</creatorcontrib><creatorcontrib>Maadani, Mohsen</creatorcontrib><creatorcontrib>Kiani, Reza</creatorcontrib><creatorcontrib>Shakerian, Farshad</creatorcontrib><creatorcontrib>Sanati, Hamid Reza</creatorcontrib><creatorcontrib>Zahedmehr, Ali</creatorcontrib><creatorcontrib>Nabavi, Seyedabbas</creatorcontrib><creatorcontrib>Heidarali, Mona</creatorcontrib><title>Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention</title><title>International urology and nephrology</title><addtitle>Int Urol Nephrol</addtitle><addtitle>Int Urol Nephrol</addtitle><description>Background Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CI-AKI and various agents tested for its prevention. There is currently a general agreement that adequate pre-procedural hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested IV magnesium sulfate (Mg) for CI-AKI prevention. Method and design This study is a prospective, randomized, open-labeled, single-center clinical trial. We randomly assigned 122 consecutive patients to two groups. The first group was the control group with routine treatment ( n  = 64), and second group was the study group with routine treatment plus IV magnesium sulfate 1 g just before the procedure ( n  = 62). Serum creatinine was measured before the procedure and 2 days after the procedure. The primary end point was the occurrence of CI-AKI within 48 h. CI-AKI was defined as 0.5 mg/dl or more increase in serum creatinine or 25 % or more increase above baseline serum creatinine. There was no difference in definition if both of these parameters were present. Results The control and study groups were comparable in the overall predicted risk of CI-AKI. Also, the type and volume of the contrast were not significantly different between the two groups. Following angioplasty, CI-AKI occurred in 17 (26.6 %) patients in the control group and nine (14.5 %) patients in the study group; there was a significant reduction in CI-AKI in the study group ( P  = 0.01). Additionally, there was no mortality or a need for hemodialysis in either group. Conclusion In primary PCI patients, the prophylactic use of intravenous Mg can be recommended to be added to traditional hydration for CI-AKI prevention.</description><subject>Acute Kidney Injury - blood</subject><subject>Acute Kidney Injury - chemically induced</subject><subject>Acute Kidney Injury - prevention &amp; control</subject><subject>Administration, Intravenous</subject><subject>Aged</subject><subject>Calcium Channel Blockers - administration &amp; dosage</subject><subject>Contrast Media - adverse effects</subject><subject>Creatinine - blood</subject><subject>Female</subject><subject>Humans</subject><subject>Magnesium Sulfate - administration &amp; dosage</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Nephrology - Original Paper</subject><subject>Percutaneous Coronary Intervention - adverse effects</subject><subject>Prospective Studies</subject><subject>Urology</subject><issn>0301-1623</issn><issn>1573-2584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kUFrFTEUhYMo9rX6A9xIwI2b6E1mJsm4k6K1UHCj65CXuemb8iYZk4zS7v3fZpiniOAqkPudc8_lEPKCwxsOoN5mzkXXMeAtA90De3hEdrxTDROdbh-THTTAGZeiOSPnOd8BQK8BnpIz0bWq473ckZ_XoST7HUNcMp3sbcA8LhPNy9Hbgu9owB90wnKIAx0DnRNWtIwx0Oipi6s2FzaGYXE4VHg-pDjbcrjf6HGy6Z7OmNxSbMB1h4sphvV3DAXTye0ZeeLtMePz03tBvn788OXyE7v5fHV9-f6GubYVhXmLznrfDVZDi7aRqLV3LbS95koj94hO4OD6Opda7tu9En3jh0ZJEF72zQV5vfnOKX5bMBczjdnh8biFM1x2vVIgJa_oq3_Qu7ikUNOtlG5qAqEqxTfKpZhzQm9ORxsOZu3IbB2Z2pFZOzIPVfPy5LzsJxz-KH6XUgGxAbmOwi2mv1b_1_UXgo6hOw</recordid><startdate>20150301</startdate><enddate>20150301</enddate><creator>Firouzi, Ata</creator><creator>Maadani, Mohsen</creator><creator>Kiani, Reza</creator><creator>Shakerian, Farshad</creator><creator>Sanati, Hamid Reza</creator><creator>Zahedmehr, Ali</creator><creator>Nabavi, Seyedabbas</creator><creator>Heidarali, Mona</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20150301</creationdate><title>Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention</title><author>Firouzi, Ata ; Maadani, Mohsen ; Kiani, Reza ; Shakerian, Farshad ; Sanati, Hamid Reza ; Zahedmehr, Ali ; Nabavi, Seyedabbas ; Heidarali, Mona</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-faecaff5da804ea36e88fc40498178e1feec2edc9a80686b4b7293fd37602f693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acute Kidney Injury - blood</topic><topic>Acute Kidney Injury - chemically induced</topic><topic>Acute Kidney Injury - prevention &amp; control</topic><topic>Administration, Intravenous</topic><topic>Aged</topic><topic>Calcium Channel Blockers - administration &amp; dosage</topic><topic>Contrast Media - adverse effects</topic><topic>Creatinine - blood</topic><topic>Female</topic><topic>Humans</topic><topic>Magnesium Sulfate - administration &amp; dosage</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Nephrology - Original Paper</topic><topic>Percutaneous Coronary Intervention - adverse effects</topic><topic>Prospective Studies</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Firouzi, Ata</creatorcontrib><creatorcontrib>Maadani, Mohsen</creatorcontrib><creatorcontrib>Kiani, Reza</creatorcontrib><creatorcontrib>Shakerian, Farshad</creatorcontrib><creatorcontrib>Sanati, Hamid Reza</creatorcontrib><creatorcontrib>Zahedmehr, Ali</creatorcontrib><creatorcontrib>Nabavi, Seyedabbas</creatorcontrib><creatorcontrib>Heidarali, Mona</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International urology and nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Firouzi, Ata</au><au>Maadani, Mohsen</au><au>Kiani, Reza</au><au>Shakerian, Farshad</au><au>Sanati, Hamid Reza</au><au>Zahedmehr, Ali</au><au>Nabavi, Seyedabbas</au><au>Heidarali, Mona</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention</atitle><jtitle>International urology and nephrology</jtitle><stitle>Int Urol Nephrol</stitle><addtitle>Int Urol Nephrol</addtitle><date>2015-03-01</date><risdate>2015</risdate><volume>47</volume><issue>3</issue><spage>521</spage><epage>525</epage><pages>521-525</pages><issn>0301-1623</issn><eissn>1573-2584</eissn><coden>IURNAE</coden><abstract>Background Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CI-AKI and various agents tested for its prevention. There is currently a general agreement that adequate pre-procedural hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested IV magnesium sulfate (Mg) for CI-AKI prevention. Method and design This study is a prospective, randomized, open-labeled, single-center clinical trial. We randomly assigned 122 consecutive patients to two groups. The first group was the control group with routine treatment ( n  = 64), and second group was the study group with routine treatment plus IV magnesium sulfate 1 g just before the procedure ( n  = 62). Serum creatinine was measured before the procedure and 2 days after the procedure. The primary end point was the occurrence of CI-AKI within 48 h. CI-AKI was defined as 0.5 mg/dl or more increase in serum creatinine or 25 % or more increase above baseline serum creatinine. There was no difference in definition if both of these parameters were present. Results The control and study groups were comparable in the overall predicted risk of CI-AKI. Also, the type and volume of the contrast were not significantly different between the two groups. Following angioplasty, CI-AKI occurred in 17 (26.6 %) patients in the control group and nine (14.5 %) patients in the study group; there was a significant reduction in CI-AKI in the study group ( P  = 0.01). Additionally, there was no mortality or a need for hemodialysis in either group. Conclusion In primary PCI patients, the prophylactic use of intravenous Mg can be recommended to be added to traditional hydration for CI-AKI prevention.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>25475196</pmid><doi>10.1007/s11255-014-0890-z</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0301-1623
ispartof International urology and nephrology, 2015-03, Vol.47 (3), p.521-525
issn 0301-1623
1573-2584
language eng
recordid cdi_proquest_miscellaneous_1659770661
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Acute Kidney Injury - blood
Acute Kidney Injury - chemically induced
Acute Kidney Injury - prevention & control
Administration, Intravenous
Aged
Calcium Channel Blockers - administration & dosage
Contrast Media - adverse effects
Creatinine - blood
Female
Humans
Magnesium Sulfate - administration & dosage
Male
Medicine
Medicine & Public Health
Middle Aged
Nephrology
Nephrology - Original Paper
Percutaneous Coronary Intervention - adverse effects
Prospective Studies
Urology
title Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T11%3A27%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenous%20magnesium%20sulfate:%20new%20method%20in%20prevention%20of%20contrast-induced%20nephropathy%20in%20primary%20percutaneous%20coronary%20intervention&rft.jtitle=International%20urology%20and%20nephrology&rft.au=Firouzi,%20Ata&rft.date=2015-03-01&rft.volume=47&rft.issue=3&rft.spage=521&rft.epage=525&rft.pages=521-525&rft.issn=0301-1623&rft.eissn=1573-2584&rft.coden=IURNAE&rft_id=info:doi/10.1007/s11255-014-0890-z&rft_dat=%3Cproquest_cross%3E3605313261%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1658380427&rft_id=info:pmid/25475196&rfr_iscdi=true